UnitedHealth Group (NYSE:UNH) had its target price lowered by equities research analysts at Morgan Stanley from $315.00 to $285.00 in a note issued to investors on Wednesday, April 17th, TipRanks reports. The brokerage presently has an “overweight” rating on the healthcare conglomerate’s stock. Morgan Stanley’s target price points to a potential upside of 18.46% from the company’s current price.
A number of other research firms have also weighed in on UNH. ValuEngine lowered UnitedHealth Group from a “buy” rating to a “hold” rating in a research note on Wednesday, February 27th. Credit Suisse Group reiterated a “buy” rating and issued a $310.00 target price on shares of UnitedHealth Group in a research report on Friday, February 8th. Oppenheimer boosted their target price on UnitedHealth Group from $300.00 to $305.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 16th. Zacks Investment Research downgraded UnitedHealth Group from a “buy” rating to a “hold” rating in a research report on Tuesday, March 19th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $310.00 price objective on shares of UnitedHealth Group in a research report on Tuesday, January 15th. One analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $290.47.
NYSE:UNH traded up $2.62 during trading hours on Wednesday, reaching $240.59. 4,373,591 shares of the company traded hands, compared to its average volume of 8,753,273. UnitedHealth Group has a 1 year low of $208.07 and a 1 year high of $287.94. The company has a current ratio of 0.73, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $226.15 billion, a price-to-earnings ratio of 18.68, a PEG ratio of 1.27 and a beta of 0.74.
In other news, CEO David S. Wichmann acquired 20,000 shares of the company’s stock in a transaction that occurred on Friday, May 3rd. The shares were bought at an average price of $231.79 per share, with a total value of $4,635,800.00. Following the completion of the purchase, the chief executive officer now directly owns 904,367 shares in the company, valued at $209,623,226.93. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gail R. Wilensky sold 2,930 shares of the stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $253.39, for a total value of $742,432.70. Following the completion of the transaction, the director now directly owns 64,726 shares in the company, valued at approximately $16,400,921.14. The disclosure for this sale can be found here. Over the last quarter, insiders sold 27,930 shares of company stock worth $6,746,683. Company insiders own 0.87% of the company’s stock.
A number of large investors have recently made changes to their positions in UNH. CI Investments Inc. boosted its position in UnitedHealth Group by 5.8% during the 3rd quarter. CI Investments Inc. now owns 949,719 shares of the healthcare conglomerate’s stock valued at $252,663,000 after acquiring an additional 52,023 shares in the last quarter. Martingale Asset Management L P boosted its position in UnitedHealth Group by 1.7% during the 3rd quarter. Martingale Asset Management L P now owns 214,133 shares of the healthcare conglomerate’s stock valued at $56,969,000 after acquiring an additional 3,598 shares in the last quarter. Blue Fin Capital Inc. boosted its position in UnitedHealth Group by 7.2% during the 3rd quarter. Blue Fin Capital Inc. now owns 10,689 shares of the healthcare conglomerate’s stock valued at $2,844,000 after acquiring an additional 722 shares in the last quarter. Capital Guardian Trust Co. boosted its position in UnitedHealth Group by 0.6% during the 3rd quarter. Capital Guardian Trust Co. now owns 276,790 shares of the healthcare conglomerate’s stock valued at $73,637,000 after acquiring an additional 1,571 shares in the last quarter. Finally, Bamco Inc. NY boosted its position in UnitedHealth Group by 230.0% during the 3rd quarter. Bamco Inc. NY now owns 2,419 shares of the healthcare conglomerate’s stock valued at $644,000 after acquiring an additional 1,686 shares in the last quarter. 87.49% of the stock is currently owned by institutional investors.
UnitedHealth Group Company Profile
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.
Read More: What is a Tariff?
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.